Skip to main content

Table 2 Multivariate analysis of prognostic factors in 491 nasopharyngeal carcinoma patients receiving IMRT

From: The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy

Endpoint

Variable

HR

HR (95 % CI)

P value

OS

N Stage(0)

Ref

Ref

0.001

 

N Stage(1)

1.172

0.252- 5.453

0.839

 

N Stage(2)

1.767

0.393- 7.950

0.458

 

N Stage(3)

7.404

1.494- 36.684

0.014

 

Low-dose group

Ref

Ref

0.001

 

Median-dose group

0.135

0.045-0.405

<0.001

 

High-dose group

0.225

0.069-0.734

0.013

 

EBV DNA

4.953

2.200-11.153

<0.001

DMFS

EBV DNA

3.669

2.058-6.540

<0.001

  1. HR hazard ratio, CI confidence interval, Ref reference, OS overall survival, DMFS distant metastasis free survival, EBV DNA Epstein–Barr virus deoxyribonucleic acid. P value < 0.05 is statistically significant
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us